TuisBMRN • NASDAQ
add
Biomarin Pharmaceutical Inc
Vorige sluiting
$55,91
Dagwisseling
$54,05 - $56,07
Jaarwisseling
$52,93 - $85,00
Markkapitalisasie
10,39 mjd USD
Gemiddelde volume
2,29 m
P/V-verhouding
16,02
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 825,41 m | 15,92% |
Bedryfskoste | 237,12 m | -14,50% |
Netto inkomste | 240,53 m | 124,43% |
Netto winsgrens | 29,14 | 93,62% |
Wins per aandeel | 1,44 | 50,00% |
EBITDA | 295,45 m | 101,10% |
Effektiewe belastingkoers | 19,25% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,43 mjd | 16,97% |
Totale bates | 7,46 mjd | 5,51% |
Totale aanspreeklikheid | 1,43 mjd | -19,74% |
Totale ekwiteit | 6,03 mjd | — |
Uitstaande aandele | 192,01 m | — |
Prys om te bespreek | 1,78 | — |
Opbrengs op bates | 9,48% | — |
Opbrengs op kapitaal | 10,63% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 240,53 m | 124,43% |
Kontant van bedrywe | 185,27 m | 56,00% |
Kontant van beleggings | -12,59 m | -113,92% |
Kontant van finansiering | -4,60 m | -136,50% |
Netto kontantverandering | 165,01 m | -26,71% |
Beskikbare kontantvloei | 97,11 m | 1 639,76% |
Meer oor
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
Gestig
Mrt. 1997
Webwerf
Werknemers
3 040
